<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02438995</url>
  </required_header>
  <id_info>
    <org_study_id>15-182</org_study_id>
    <nct_id>NCT02438995</nct_id>
  </id_info>
  <brief_title>Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>Phase I Trial of Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized, two arm, Phase I research study of superselective&#xD;
      intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of&#xD;
      recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) of superselective intraarterial Cetuximab.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive frequency of subjects experiencing toxicities.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Cetuximab with Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For subjects receiving radiation therapy, the treatment schedule will consist of a re-irradiation dose of approximately 70 Gy over 6-7 weeks. This experimental treatment arm will add IA Cetuximab administration every three weeks up to 2 doses to this radiation schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For subjects who are not candidates for re-irradiation, this experimental treatment arm will include only IA Cetuximab administration every three weeks up to 2 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraarterial Cetxuimab (Erbitux)</intervention_name>
    <description>Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)</description>
    <arm_group_label>Cetuximab Alone</arm_group_label>
    <arm_group_label>Cetuximab with Radiation Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients of ≥18 years of age.&#xD;
&#xD;
          2. Patients with a documented diagnosis of recurrent head and neck squamous cell cancer&#xD;
             (squamous cell carcinoma, including nasopharyngeal cancer, or adenoid cystic&#xD;
             carcinoma).&#xD;
&#xD;
             Patients must have at least one confirmed and evaluable tumor site.* The recurrence&#xD;
             must have bidimensional measurements by clinical examination or CT/MRI/PET scan. A&#xD;
             confirmed recurrence site may also be biopsy-proven&#xD;
&#xD;
          3. Tumor Recurrence which is surgically unresectable&#xD;
&#xD;
          4. Patients must have a Karnofsky performance status ≥70% (or the equivalent ECOG level&#xD;
             of 0-2) (see Appendix Performance Status Evaluation) and an expected survival of ≥&#xD;
             three months.&#xD;
&#xD;
          5. Patients must have adequate hematologic reserve with WBC≥3000/mm3, absolute&#xD;
             neutrophils ≥1500/mm3 and platelets ≥100,000/ mm3. Patients who are on Coumadin must&#xD;
             have a platelet count of ≥150,000/ mm3&#xD;
&#xD;
          6. Pre-enrollment chemistry parameters must show: bilirubin&lt;1.5X the institutional upper&#xD;
             limit of normal (IUNL); AST or ALT&lt;2.5X IUNL and creatinine&lt;1.5X IUNL.&#xD;
&#xD;
          7. Pre-enrollment coagulation parameters (PT and PTT) must be ≤1.5X the IUNL.&#xD;
&#xD;
          8. Patients must agree to use a medically effective method of contraception during and&#xD;
             for a period of three months after the treatment period. A pregnancy test will be&#xD;
             performed on each premenopausal female of childbearing potential immediately prior to&#xD;
             entry into the research study.&#xD;
&#xD;
          9. Patients must be able to understand and give written informed consent. Informed&#xD;
             consent must be obtained at the time of patient screening.&#xD;
&#xD;
         10. Patients who refuse surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or lactating.&#xD;
&#xD;
          2. Women of childbearing potential and fertile men will be informed as to the potential&#xD;
             risk of procreation while participating in this research trial and will be advised&#xD;
             that they must use effective contraception during and for a period of three months&#xD;
             after the treatment period.&#xD;
&#xD;
          3. Patients with significant intercurrent medical or psychiatric conditions that would&#xD;
             place them at increased risk or affect their ability to receive or comply with&#xD;
             treatment or post-treatment clinical monitoring.&#xD;
&#xD;
          4. Pre-existing cardiac or respiratory disorders&#xD;
&#xD;
          5. Unrelated malignancy within 3 years&#xD;
&#xD;
          6. History of hypersensitivity reactions to other EGFR inhibitors&#xD;
&#xD;
          7. Metastatic disease&#xD;
&#xD;
          8. Less than 6 months from prior Radiation Therapy (Arm 1)&#xD;
&#xD;
          9. Previous exposure to Cetuximab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Boockvar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>John Boockvar, MD Zucker SOM @Hofstra/Northwell</investigator_full_name>
    <investigator_title>Professor of Neurosurgery and Otolaryngology/Head and Neck Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

